Typhoid vaccine development with a human challenge model.

Feasey, Nicholas ORCID: https://orcid.org/0000-0003-4041-1405 and Levine, Myron (2017) 'Typhoid vaccine development with a human challenge model.'. Lancet, Vol 390, Issue 10111, pp. 2419-2421.

Preview

Text Lancet_Feasey_28_9_17.pdf - Published Version Available under License Creative Commons Attribution. Download (463kB) | Preview

Abstract

Experimental human typhoid fever challenge was first described in 1896 by Wright, who vaccinated two men against typhoid fever and challenged one with what was then known as Salmonella typhosa.1 While challenge models are sometimes controversial, they offer enormous potential to study the pathogenesis of disease and to accelerate vaccine development, particularly in human-restricted pathogens such as Salmonella enterica serovar Typhi. The Maryland typhoid human challenge model, which ran from 1952 to 1974, led to insights into typhoid fever and facilitated the development of live attenuated typhoid vaccine Ty21a.

Item Type:	Article
Subjects:	QV Pharmacology > Drug Standardization. Pharmacognosy. Medicinal Plants > QV 744 Pharmaceutical chemistry QV Pharmacology > Drug Standardization. Pharmacognosy. Medicinal Plants > QV 771 Standardization and evaluation of drugs W General Medicine. Health Professions > W 20.5 Biomedical research WC Communicable Diseases > Infection. Bacterial Infections > Enteric Infections > WC 270 Typhoid fever
Faculty: Department:	Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):	https://doi.org/10.1016/S0140-6736(17)32407-8
SWORD Depositor:	JISC Pubrouter
Depositing User:	Stacy Murtagh
Date Deposited:	20 Oct 2017 15:05
Last Modified:	03 Aug 2018 15:40
URI:	https://archive.lstmed.ac.uk/id/eprint/7686

Statistics

View details

Actions (login required)

Edit Item